A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

April 15, 2023

Study Completion Date

July 7, 2023

Conditions
NASH With Fibrosis
Interventions
DRUG

rencofilstat, 75 mg

1 softgel capsule

DRUG

rencofilstat, 150mg

2 softgel capsules

DRUG

rencofilstat, 225 mg

3 softgel capsules

Trial Locations (20)

28304

Coastal Reseach Institute, Fayetteville

32127

Progressive Medical Research, Port Orange

33016

Evolution Clinical Trials, Inc., Hialeah Gardens

33912

Covenant Metabolic Specialists-Fort Myers, Fort Myers

34208

Synergy Healthcare, LLC, Bradenton

34240

Covenant Metabolic Specialists-Sarasota, Sarasota

43235

Optimed Research, Columbus

44145

Clinical Research Institute of Ohio, Westlake

48047

Clinical Research Institute of Michigan, Chesterfield

77401

Apex Mobile Clinical Research, Bellaire

78229

Pinnacle Clinical Research-San Antonio, San Antonio

78539

South Texas Research Institute, Edinburg

78626

Pinnacle Clinical Research-Georgetown, Georgetown

78757

Pinnacle Clinical Research-Austin, Austin

85224

Arizona Liver Health-Chandler, Chandler

85381

Arizona Liver Health-Glendale, Peoria

85712

Adobe Clinical Research, LLC, Tucson

Arizona Liver Health-Tucson, Tucson

91911

Velocity Clinical Research-Chula Vista, Chula Vista

91942

Velocity Clinical Research-San Diego, La Mesa

Sponsors
All Listed Sponsors
lead

Hepion Pharmaceuticals, Inc.

INDUSTRY